YAP1 and hepatocellular carcinoma: The molecule has demonstrated strong antitumor effects in multiple cancer models, including esophageal adenocarcinoma [16], mesothelioma [17], hepatocellular carcinoma [18], and cholangiocarcinoma [19], particularly in tumors enriched with YAP-driven cancer stem cell populations.